Table 2.
The comparison of mean baseline and follow-up clinical assessment results of 9 Taiwanese patients with mucopolysaccharidosis VI underwent enzyme replacement therapy for 6.2–11.2 years.
| Clinical assessments | N | Baseline | Follow-up | Improvement (%) |
|---|---|---|---|---|
| Urinary GAG (μg/mg creatinine) | 9 | 453.4 | 139 | 69% |
| 6-min walk (m) | 6 | 254 | 404 | 59% |
| 3-min stair climb (stairs) | 3 | 131 | 191 | 46% |
| Coins picking up (sec) | 3 | 44 | 29 | 33% |
| Disability Index | 9 | 1.96 | 1.54 | 21% |
| FEV1 (L) | 4 | 0.50 | 0.79 | 59% |
| FVC (L) | 4 | 0.54 | 0.96 | 80% |
GAG, glycosaminoglycan; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.